This phase I/II trial is evaluating two biological therapies (Nivolumab alone and in combination with Ipilimumab) in children and adolescents that have been diagnosed with advanced Central Nervous System (CNS) cancers .
This trial is treating patients with CNS cancers, including High Grade Glioma (HGG), Medulloblastoma and Ependymoma.
This is a systemic therapy trial.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Subjects With High Grade Primary CNS Malignancies
Bristol-Myers Squibb (BMS)
The purpose of this study is to determine the safety and effectiveness of nivolumab alone and in combination with ipilimumab in pediatric patients with high grade primary central nervous system (CNS) malignancies
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More